Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

@article{Bermejo2017MepolizumabFT,
  title={Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal},
  author={I{\~n}igo Bermejo and M. D. Stevenson and Katy Cooper and Sue Harnan and Jean Hamilton and Mark Clowes and Christopher Carroll and Tim W. Harrison and Shironjit Saha},
  journal={PharmacoEconomics},
  year={2017},
  volume={36},
  pages={131-144}
}
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab (Nucala®) to submit evidence on the clinical and cost effectiveness of mepolizumab for the treatment of severe eosinophilic asthma. The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at the University of Sheffield was commissioned to act as the independent evidence review group… 
16 Citations
Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
TLDR
The cost comparison between mepolizumab and omalizumAB in immunoglobulin E mediated eosinophilic asthma patients suggests a use of the lower cost drug, promoting price competition.
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore.
TLDR
At its current price, mepolizumab is not considered a cost-effective use of healthcare resources in Singapore and substantial price reductions are required to improve its cost-effectiveness to an acceptable range.
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life☆
TLDR
Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy and the annual total cost per patient pre- and post-MEP was €3996 and €1,527, respectively.
The spectrum of therapeutic activity of mepolizumab
TLDR
The efficacy of mepolizumab in eosinophilic asthma is clearly demonstrated by a number of controlled trials and by meta-analyses.
Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden
TLDR
It is demonstrated that benralizumab has a high probability of being cost-effective compared with SOC plus OCS for a subgroup of patients with severe, eosinophilic asthma receiving regular OCS treatment and may support clinicians, payers and patients in making treatment decisions.
Real-life cost-effectiveness of benralizumab in patients with severe asthma
TLDR
All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
TLDR
Most studies recommended carefully targeting biological therapy to specific populations such as responders or discounting acquisition price in order to further improve value, and key drivers of cost-effectiveness included day-to-day health-related quality of life, asthma-related mortality, acquisition price of the biological therapy, and time horizon.
2019 ARIA Care pathways for allergen immunotherapy
TLDR
Care pathways for AIT are reviewed using strict criteria and simple recommendations are provided that can be used by all stakeholders including healthcare professionals.
COVID vaccination and asthma exacerbation: might there be a link?
TLDR
A challenging case of severe asthma exacerbation that a 28-year-old female patient developed after receiving two doses of mRNA-based vaccine BNT162b2 at the Hospital, IRCCS Policlinico San Matteo of Pavia, in Northern Italy is examined.
Real‐world experience with mepolizumab: Does it deliver what it has promised?
  • F. Schleich, S. Graff, +7 authors R. Louis
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2020
Randomized control trials performed in selected populations of severe eosinophilic asthmatics have shown that mepolizumab, an anti‐IL5 therapy, was able to reduce exacerbations and OCS maintenance
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
TLDR
Omalizumab significantly reduced the incidence of CS exacerbations in both adults and children, and the cost-effectiveness of omalizuab was assessed from the perspective of the UK NHS in the two separate populations: adults and adolescents, and children.
Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
TLDR
Adding omalizumab to BSC is efficacious in patients with inadequately controlled severe persistent allergic asthma despite high-dose ICS plus a long-acting beta(2)-agonist (LABA) (EU label population), with further efficacy observed in patients judged to have responded to therapy which may more accurately illustrate the actual benefit of omalzumab therapy in clinical practice.
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
TLDR
Mepolizumab treatment was shown to exert a durable response, with patients who previously received mepolizumAB in MENSA or SIRIUS maintaining reductions in exacerbation rate and OCS dosing throughout COSMOS.
Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial
TLDR
To elucidate the efficacy, safety, and patient characteristics of responsiveness to mepolizumab (a humanized monoclonal antibody against interleukin 5), a large number of patients with severe, eosinophilic asthma were enrolled in 81 multinational centers.
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
TLDR
Omalizumab provided additional clinical benefit for patients with severe allergic asthma that is inadequately controlled with high-dose ICS and LABA therapy, and the rate of protocol-defined asthma exacerbations was significantly reduced.
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
TLDR
In patients requiring daily oral glucocorticoid therapy to maintain asthma control, mepolizumab had a significant glucoc Corticoid-sparing effect, reduced exacerbations, and improved control of asthma symptoms.
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
TLDR
Recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults and coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy are provided.
Diagnosis and management of eosinophilic asthma: a US perspective
TLDR
The present review provides a summary of the clinical features, pathogenesis, diagnosis, and management of eosinophilic asthma.
Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice.
TLDR
The evidence for FeNO as a predictor of Th2-mediated inhaled corticosteroid responsive airway inflammation is examined and FeNO may be useful in identifying patients at risk for future impairment or loss of asthma control during reduction/cessation of ICS treatment.
...
1
2
3
...